N11 ERBB2 in SCLC immune response (Meder)
Deciphering ERBB2 dependent immune regulation in small cell lung cancer (SCLC)
Term: 01.04.2024 – 31.03.2026
My preliminary results suggest that ERBB2 is upregulated in SCLC during metastasis and resistance to immune checkpoint blockade (ICB), helping the tumor to escape the immune system. We plan to investigate ERBB2 inhibitors regarding their immunoregulatory properties ex vivo in precision cut tissue slices (PCTS) and in a SCLC mouse model. We will elucidate the underlying molecular mechanisms downstream of ERBB2 and identify patients who may benefit from an ERBB2 targeted therapy.
